文献速递免疫规划

新型猪瘟标记活疫苗候选株的安全性、效力及DIVA可行性

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate.
PubMed 文献 · Vaccine · 2022-10-31

本研究基于删除猪瘟病毒Erns蛋白H79和C171两个毒力相关功能残基及引入E2蛋白S14K、G22A、E24R、G25D替换构建双缺失标记活疫苗候选株GD18-ddErnHC-KARD,在仔猪中评估其安全性和效力,并验证配套DIVA ELISA的鉴别诊断可行性。

要点

  • 高剂量105.0 TCID50候选株不引起发热、临床症状或病理损伤,接种后21天未检出排毒。
  • 低剂量103.0 TCID50候选株在强毒石门株攻击后提供完全临床保护且未检出排毒。
  • 配套DIVA ELISA可区分感染动物与接种动物。

核心结论

  • 研究结果为理性设计猪瘟抗原标记修饰活疫苗候选株提供了概念验证。

研究设计与样本

  • 基于流行2.1基因型猪瘟病毒株,删除Erns蛋白H79和C171两个毒力相关功能残基,并引入E2蛋白S14K、G22A、E24R、G25D四个替换作为阴性血清学标记,构建双缺失标记MLV候选株GD18-ddErnHC-KARD,在仔猪中评估安全性和效力。

主要发现

  • 安全性研究显示,高剂量105.0 TCID50候选株不引起发热、临床症状或病理损伤,接种后21天未检出排毒。
  • 效力研究显示,低剂量103.0 TCID50候选株在强毒石门株攻击后提供完全临床保护且未检出排毒。
  • 配套DIVA ELISA可区分感染动物与接种动物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classical swine fever virus (CSFV) is the etiological agent of classical swine fever, a highly contagious disease that causes significant economic losses to the swine industry. Systemic prophylactic immunization with the live attenuated vaccine, the C-strain vaccine, is one of the effective measures for CSF control. However, one of the limitations of the C-strain vaccine is that the field strains-infected animals cannot be differentiated from the C-strain vaccinated herds by serological tests (DIVA). This constraint hampers the practical usage of the C-strain vaccine to eradicate the CSF in China. In the current study, a novel CSF modified live marker vaccine candidate was constructed based on the attenuation of the prevalent 2.1 genotype strain by the deletion of two virulence associated functional residues in the CSFV Erns, H79, and C171. Meanwhile, four residues S14, G22, E24, and E25 were identified specifically for the 6B8 mAb binding to the CSFV E2 as the novel conformational epitope. Then four substitutions of S14K, G22A, E24R, and G25D were further incorporated in the double deletion construct as a negative serological marker. Finally, the double-deletion marker MLV candidate GD18-ddErnHC-KARD was rescued, and its safety and efficacy profiles were evaluated in piglets. The safety study results indicated that the candidate did not induce fever, clinical signs, or pathological lesions with a high dose of 105.0 TCID50, and in addition, no virus shedding was detected until 21 days post-inoculation. Meanwhile, the efficacy study results demonstrated that at a low dose of 103.0 TCID50, it conferred complete clinical protection and no virus shedding was detected after the challenge with a highly virulent Shimen strain. Importantly, the infected animals were differentiated using the accompanied DIVA ELISA. These results constitute a proof-of-concept for rationally designing a CSF antigenically marked modified live vaccine candidate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tong C, Liu H, Wang J, et al. Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate. Vaccine. 2022. PMID: 36328881. doi:10.1016/j.vaccine.2022.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。